echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Five years later, 60% of patients are still in remission for the long-term effects of CAR-T therapy

    Five years later, 60% of patients are still in remission for the long-term effects of CAR-T therapy

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Kymriah is the first CAR-T therapy to be approved by the FDA.
    by targeting CD19 antigens on the surface of B cells, allowing modified CAR-T cells to destroy B lymphocytes in the blood.
    the study, the researchers followed patients with diffuse large B-cell lymphoma (DLBCL) and recurring/refractic folytic lymphoma treated with Kymriah.
    46% of the 24 DLBCL patients were in complete remission after five years.
    71% of the 14 patients with relapsed/refratic folytic lymphoma were still in complete remission after 5 years.
    also assessed the persistence of CAR-T cells in patients.
    they found that 50 percent of patients with a remission period of more than one year did not have GENETIC modification of chised antigen receptors that expressed CD19 in their bodies after five years.
    only one of the 18 patients who relapsed within a year of being treated with CAR-T cell therapy was genetically modified.
    this result means that the loss of CAR-T cells may not be a common cause of therapeutic resistance.
    "We found that the majority of patients who had a remission period of more than one year after receiving CAR-T cell therapy were still in remission after five years.
    it's very exciting and shows the durability of this treatment. Dr. Elise A. Chong of the Department of Hematology/Oncology at the University of Pennsylvania School of Medicine, co-author of the
    study, said, "For patients who do not respond to chemotherapy, this provides a treatment option that may lead to long-term remission."
    : This article is intended to introduce medical and health research, not treatment options recommended.
    if you need guidance on treatment options, visit a regular hospital.
    a reference: s1 s penn-developed CAR T therapy show long-lasting remissions in non-hodgkin lymphoma. Retrieved February 18, 2021, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.